Ophthalmic Pharmaceutical Markets Are Expanding and Growing Globally. This Review Research Report Gives A Glimpse Of The Current Pharmaceutical Market Globally And Compares The International Ophthalmic Drug Markets With The Scenario In Ophthalmic Pharmaceutical Markets Are Expanding And Growing Globally. The Ophthalmology Drug Development Pipeline Is Looking Healthy With Over According To Our Experts Analysis By 600 Ophthalmology Drug R&D Products Being Developed For Almost 1,000 Ophthalmic Indications
Market Highlights
It Is Estimated That The Ophthalmic Drugs Market Is Expected To Grow At A CAGR 6.0% During The Forecast Period Of 2017 To 2023.
Owing to the rising cases of eye diseases, the demand for an effective treatment option has also been escalating. In the recent years, various new and existing marketers have come up with effective drugs. For instance, in November 2017, Bausch & Lomb, a U.S.-based company, received the FDA approval for Vyzulta (latanoprostene bunod ophthalmic solution). The drug is designed for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.
A number of factors such as rising prevalence of eye diseases, growing awareness, huge research funding in ophthalmology, unmet medical needs, rising competition among market players, improving regulatory framework, aging population, and increasing government assistance, are a few factors propelling the growth of the global ophthalmic drugs market. According to the 2017 statistics suggested by the World Health Organization (WHO), the chronic eye disease is the main cause of vision loss, globally.
However, the high cost associated with a diagnosis of eye diseases, side effects of available treatment options, and lack of healthcare insurance may hamper the growth of the market.
Key Players
Some of the key players in the global ophthalmic drugs market are Actavis Generics, Allergan Plc, Bausch & Lomb Inc., Genentech, Inc., Merck & Co., Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Shire Plc, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., and others.
Fill Out Details To Receive FREE Sample Here: https://www.marketresearchfuture.com/sample_request/5753
Key Finding
In November 2017, Bausch & Lomb, a U.S.-based company, received the FDA approval for Vyzulta (latanoprostene bunod ophthalmic solution). The drug is designed for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.
In December 2017, Rhopressa (netarsudil ophthalmic solution) by Aerie Pharmaceuticals has also received the FDA approval for the treatment of glaucoma or ocular hypertension.
Europe holds the second position in the ophthalmic drugs market. It is expected that the government support towards research and development expenditure, increasing competition among marketers, and amendments in reimbursement policies in healthcare are likely to drive the European market.
Asia Pacific is the fastest growing ophthalmic drugs market owing to a huge patient pool, increasing demand, and development in healthcare technology.
The Middle East and Africa hold the lowest share of the global ophthalmic drugs market due to low development, lack of technical knowledge, and poor medical facilities.
Segmentation
The global ophthalmic drugs market is segmented on the basis of indication, drug class, type of dosage, product, distribution channel.
On the basis of indication, the market is classified as glaucoma, retinal disorders, inflammation/infection, dry eye, allergies, uveitis, and others.
On the basis of the drug class, the market is classified as antiallergy, anti-VEGF agents, anti-inflammatory, antiglaucoma, and others. The anti-inflammatory class is further segmented into nonsteroidal drugs and steroidal drugs.
On the basis of type of dosage, the market is classified as eye drops, eye solutions, ointments, capsules and tablets, and gels.
On the basis of the product, the market is classified as prescription drugs and OTC drugs.
On the basis of the distribution channel, the market is classified as hospital pharmacies, online pharmacies, drug stores, and others.
Regional Analysis
The Americas dominates the ophthalmic drugs market owing to the presence of patient population, rising prevalence of eye diseases, well-developed technology, high healthcare expenditure, and the presence of the leading players. According to the glaucoma research foundation, in the United States, more than 120,000 are blind because of glaucoma. This accounts for 9 to 12% of all the cases of blindness. It is also reported that over 3 million Americans have glaucoma, but only a few of them know they have it. It is also reported that glaucoma accounts for more than 10 million visits to physicians each year.
Access Report Details @ https://www.marketresearchfuture.com/reports/ophthalmic-drugs-market-5753
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
+1 646 845 9312
Your information will never be shared with any third party.